Takeru Kusumoto

No ORCID on file · 3 papers in corpus · active 2017-2021

Study types

  • article 2
  • rct 1

Condition tags

  • endometriosis 3
  • chronic_pelvic_pain 2
rct 2021
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis-associated pain: phase 2 safety and efficacy 24-week results
BMC women's health ·doi:10.1186/s12905-021-01393-3

BACKGROUND: Relugolix is a once-daily, oral, nonpeptide, gonadotropin-releasing hormone receptor antagonist. The aim of this study was to evaluate safety of relugolix over 24 weeks in women with endometriosis-associated pain. METHODS: This…

article 2020
Relugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose–response manner: a randomized, double-blind, placebo-controlled study
Fertility and sterility ·doi:10.1016/j.fertnstert.2020.07.055
article 2017
Relugolix, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist, in women with endometriosis (EM)-associated pain: Phase 2 safety and efficacy 24-week results
·doi:10.1530/endoabs.49.gp134

Searchable abstracts of presentations at key conferences in endocrinology ISSN 1470-3947 (print) | ISSN 1479-6848 (online)